0
Editor's Correspondence |

Dual Antiplatelet Therapy and the Risk of Bleeding

Roy C. Ziegelstein, MD; Ariel Green, MD, MPH; Michael Sauder, MD, MPH
Arch Intern Med. 2011;171(8):782-790. doi:10.1001/archinternmed.2011.147.
Text Size: A A A
Published online

Extract

We applaud Hansen and colleagues1 for calling attention to the risk of bleeding with single or combined therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Although the authors highlight the increased risk of bleeding with all combinations of these medications, we believe that one observation in this article is worthy of special emphasis, since it is not only important but also may be unknown to many clinicians. Figure 3 of their article1(p1438) shows that the risk of bleeding for patients receiving combined treatment with aspirin and clopidogrel, often referred to as dual antiplatelet therapy (DAPT), was significantly higher than the risk for patients treated with warfarin alone. This finding should be important to clinicians who make treatment recommendations to patients with atrial fibrillation and vascular disease. It is consistent with the earlier Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE W) trial,2 in which the risk of minor bleeding and total bleeding was significantly higher for those treated with DAPT than with oral anticoagulation.

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
/>
First page PDF preview

Figures

Tables

References

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 10

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Topics
PubMed Articles
Jobs
JAMAevidence.com

Users' Guides to the Medical Literature
Example 3

brightcove.createExperiences();